Stratum | Baseline Protease-inhibitor Regimen | Use of lipid lowering therapy at study day 1 | No of baseline mutations of the NRTI classa |
---|---|---|---|
I | Atazanavir | Yes | < 2 |
II | Atazanavir | Yes | ≥2 |
III | Atazanavir | No | < 2 |
IV | Atazanavir | No | ≥2 |
V | Darunavir | Yes | < 2 |
VI | Darunavir | Yes | ≥2 |
VII | Darunavir | No | < 2 |
VIII | Darunavir | No | ≥2 |